THERAPEUTIC SLTNS INTL - TSOI STOCK NEWS

Therapeutic Solutions International has launched a landmark double-blind clinical trial for its JadiCell™ therapy targeting COVID-19 associated lung failure, involving 128 patients across multiple nations. The primary goal is to assess the survival rate and respiratory health of patients at Day 60 post-treatment. The company holds the issued patent for JadiCell and has completed prior trials with a 100% survival rate in patients under 85. The collaboration with Biorasi aims for rapid patient recruitment to expedite FDA marketing approval.

Therapeutic Solutions International announced significant advancements in their JadiCell™ adult stem cell product, which promotes the regeneration of lung tissue. Recent experiments in mice show that intravenous JadiCells preserve lung function and stimulate lung repair cells, offering hope for chronic conditions like Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF). The company is preparing to initiate a Phase III clinical trial for COVID-19-related lung failure, aiming to further validate the therapeutic potential of JadiCells.

Therapeutic Solutions International (TSOI) clarified a previous statement regarding the Principal Investigator for its clinical trial. Dr. James Veltmeyer has been appointed as the Principal Investigator pending FDA approval of TSOI as the trial's sponsor. Additionally, TSOI clarified that JadiCell adult stem cells are derived from umbilical cords and classified as mesenchymal-like stromal cells. The company focuses on immune modulation treatments for various diseases, with a commitment to advancing their clinical research.

Therapeutic Solutions International (TSOI) has appointed Biorasi as the contract research organization to conduct its Pivotal FDA Registration Clinical Trial for the JadiCell™ Adult Stem Cell Product, aimed at treating advanced COVID-19. The trial is a continuation of previous research that achieved a 100% survival rate in patients under 85. JadiCells™ show promising therapeutic activity for lung conditions. The trial will expand internationally, with India and another Latin American country involved, furthering TSOI's pursuit to be the first to market stem cell treatments for lung regeneration.

Therapeutic Solutions International (TSOI) has executed a purchase agreement for sponsorship of a pivotal Phase III clinical trial evaluating JadiCell adult stem cells for treating COVID-19 related lung failure.

Dr. Thomas Ichim emphasized the trial's impact on both COVID-19 and ARDS patients, with potential FDA registration for JadiCell as a leading cell-based therapy. The company has secured multiple patents for JadiCell, enhancing its market position. Dr. James Veltmeyer is designated as the Principal Investigator, taking control of trial conduct. TSOI acknowledges shareholder support during this significant initiative.

Therapeutic Solutions International announced the issuance of U.S. Patent #11,266,707 for its nutraceutical QuadraMune®, aimed at preventing and treating COVID-19. This patent complements a previous one covering its mechanism of action against indolamine 2,3 deoxygenase. Additionally, patent applications related to neuroprotection and neuroregeneration have been published. Company leaders emphasize the significance of these patents in validating their scientific approach to immune modulation and dual therapy strategies against COVID-19.

Therapeutic Solutions International announced a novel procedure, ApoptoCyte, enhancing the anti-inflammatory effects of mesenchymal stem cells. Data from a patent application indicates that combining apoptotic bodies with FDA-approved agents demonstrates superior therapeutic activity in animal models compared to traditional methods. This method potentially simplifies FDA approval processes due to minimal manipulation of stem cells. The company has cleared a Phase III trial for its JadiCell product in lung failure due to COVID-19, showing promising results over other stem cells.

Therapeutic Solutions International announced positive preclinical efficacy and safety data for its CampbellCell™ allogeneic primed mesenchymal stem cell therapy, targeting schizophrenia. The company previously filed a substantial patent covering stem cell approaches for treating schizophrenia in September 2020. Collaborations with Campbell Neurosciences have led to significant advancements, including recruiting industry experts and establishing a blood-based marker for suicidal tendencies. The development may represent a breakthrough in treating mental health disorders that often rely on invasive methods.

Therapeutic Solutions International has filed a new patent indicating that QuadraMune may reduce cognitive decline linked to COVID-19, based on studies conducted on mice. The experiments demonstrated a significant preservation of cognitive activity and reduced neural inflammation in mice treated with various doses of QuadraMune. This nutraceutical aims to address the long-term brain impacts of COVID-19, as highlighted by its potential anti-inflammatory and neuroregenerative effects. CEO Timothy Dixon emphasized the urgent need for effective treatments given the worsening understanding of COVID-19's aftermath.